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Received October 25, 2013; accepted January 29, 2014AbstractBackground: We investigated factors predicting postoperative recurrence in patients with pathological Stage I nonsmall cell lung cancer
(NSCLC).
Methods: All patients with clinical Stage I NSCLC who underwent surgical resection at Tri-Service General Hospital in Taiwan between January
2002 and June 2006 were reviewed retrospectively. All study patients underwent standard staging workups. We reviewed the records of 261
patients with an average follow-up of 93 months; we then included 179 patients with pathological Stage I.
Results: Two hundred sixty-one patients with clinical Stage I NSCLC were eligible. There were no significant differences in sex, tumor his-
topathology, location, and age between the two groups (recurrence and nonrecurrence), except for tumor differentiation (p ¼ 0.002), survival rate
(p < 0.001), lymphovascular space invasion (LVSI; p ¼ 0.007), advanced pathology stage (p ¼ 0.022), maximum standard uptake value
(SUVmax; p ¼ 0.027), tumor size (p < 0.011), and carcinoembryonic antigen (CEA) levels (p ¼ 0.013). Overall survival was significantly
related to postoperative recurrence (p < 0.001) in patients with pathological Stage I, in whom recurrences developed in 11.17%. Only 179
patients with pathological Stage I NSCLC, including 20 patients with postoperative recurrences, were selected. Tumor differentiation (odds ratio
3.581, p ¼ 0.058) and LVSI (odds ratio 5.374, p ¼ 0.020) were independent factors predicting recurrence.
Conclusion: Tumor differentiation and LVSI were predictors of postoperative relapse for patients with pathological stage I NSCLC. Risk factors
of postoperative recurrence in patients with pathological Stage I NSCLC may enable us to optimize the patient selection for postoperative
adjuvant therapies to prevent possibly occult micrometastases.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Nonsmall cell lung cancer (NSCLC) remains the leading
cause of cancer-related death and has a dismal prognosis.
Despite advances in radiation therapy, chemotherapy, and
newly developed molecular targeting therapies, long-term
survival after resection for patients with NSCLC remains
less than 50%. Most mortality following surgical resection is
associated with tumor recurrence. Studies have investigatedociation. All rights reserved.
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ated with decreased survival after resection for NSCLC.1,2
Accurate preoperative staging is important in determining
the appropriate treatment. It is well known that the clinical
stage does not fully predict the pathology stage. Nodal
metastasis or occult micrometastasis might be a key or link to
postoperative recurrence in patients with Stage I NSCLC.3 Our
study investigated factors predicting postoperative recurrences
in patients with pathological Stage I NSCLC. These clinico-
pathologic variables may enable us to optimize the patient
selection for adjuvant therapy in order to reduce recurrences
and improve the survival rate.
2. Methods
All patients who underwent complete resection for clinical
Stage I NSCLC at Tri-Service General Hospital, Taipei,
Taiwan, between January 2002 and June 2006, were reviewed
retrospectively. The preoperative staging workups included
chest and upper abdomen computed tomography (CT), bron-
choscopy, positron emission tomography (PET) scan, and
whole-body bone scans. Brain magnetic resonance imaging
(MRI) was routinely undertaken prior to surgery, especially
when the patients had neurogenic symptoms, such as head-
ache, dizziness, or unstable gait. Mediastinoscopy was not a
routine preoperative staging procedure, and was performed
only when enlarged mediastinal lymph nodes
(diameter > 1.0 cm) were shown by the CT scan to prove
nodal status of staging. No patients received neoadjuvant
chemotherapy. Determinations of cancer stage were based on
the tumor-node-metastasis (TNM) classification (7th edition)
of the American Joint Committee on Cancer.4 Histopathology
refers to the microscopic examination with staining methods
of surgical specimen by a pathologist, after the specimen has
been processed and histological sections have been placed
onto glass slides. The lymphovascular space invasion (LVSI)
was a histopathological examination, and the interpretation
was made by the pathologist. The findings of tumor cell within
the vascular lumen by specific stain or tumor cell infiltrated
within the surrounding lymph node tissue was called LVSI.
Serum carcinoembryonic antigen (CEA) level was measured
as part of the routine preoperative evaluation and postoperative
follow-up. Serum CEA level was calculated by means of the
two-site immunoenzymometric assay (CEA test; CIS Bio In-
ternational, Gif-sur-Yvette, France; reference range <5.0 ng/
mL) following the manufacturer's instructions. The upper limit
of normal in our hospital defined as 3.5 ng/mL based on the
95% specificity level for benign lung disease.
After evaluation of the resectability and operability of the
tumors, a total of 261 patients with clinical Stage I NSCLC
(tumor size < 5 cm, no enlarged lymph node, no direct inva-
sion to peripheral organs, and no pleural effusions) were
enrolled and underwent surgical resection with dissection of
the mediastinal lymph nodes. The indication of adjuvant
chemotherapy in our study was based on the National
Comprehensive Cancer Network Clinical Practice Guidelines
in Oncology (2009) and used in the high-risk patients, whowere defined by poorly differentiated tumor, LVSI, wedge
resection, and minimal margins. All of our patients received
complete resection with adequate surgical margins proven by
pathology. Postoperatively, patients were initially seen at 2e3
weeks after resection by the thoracic surgeon and then again
every 3e6 months at the outpatient department, where they
underwent contrast-enhanced chest CT at these appointments
during the follow-up period. The serum CEA level was
routinely measured after surgery every 3 months. Subsequent
to these visits, either a roentgenogram or CT scan of the chest
was reviewed annually. PET-CT or MRI was used as clinically
warranted. All visits were completed in concert with the
referring oncologist. Recurrence was documented either
radiographically or histologically in all cases. Secondary pri-
mary lung cancer was differentiated from recurrent NSCLC
according to the criteria proposed by Martini.5 The re-
currences included local recurrence and distant metastasis.
Clinicopathologic variables were investigated for their influ-
ence on time to postoperative recurrence. We reviewed 261
patients with an average follow-up of 93 months. Patient
consent was obtained after explaining the purpose of study and
surgical procedure.2.1. Statistical analysisDescriptive data are expressed as the mean ± standard
deviation. Student t test was used to investigate continuous
variables and the c2 test was used to compare categorical
variables between groups. Survival from the date of surgery
was calculated using KaplaneMeier survival analysis. Multi-
ple logistic regression analyses were used to identify inde-
pendent risk factors for patients with recurrences. SPSS 17.0
software (SPSS Inc., Chicago, IL, USA) was used for all an-
alyses and statistical significance was defined as p < 0.05.
3. Results
Two hundred and sixty-one patients with clinical Stage I
NSCLC after complete resection and dissection of mediastinal
lymph nodes were reviewed. Of these, 37 patients (14.2%)
developed postoperative recurrences. Twenty (7.66%) of the
total of 261 patients had distant metastases. The most common
sites of distant metastasis were brain (9/20, 45%) and bone (8/
20, 40%). Two of 20 patients had liver metastases and only
one patient had adrenal gland metastasis. Among these 20
patients, five (25%) had LVSI.
The demographic characteristics in patients with clinical
Stage I NSCLC are shown in Table 1. There were no statis-
tically significant differences in sex, tumor histopathology,
tumor location, or age (Table 1). Comparisons between two
groups showed statistical significance in tumor differentiation
(p ¼ 0.002), survival rate (p < 0.001), LVSI (p ¼ 0.007),
pathological staging (p ¼ 0.022), SUVmax of tumor
(6.60 ± 3.98 vs. 4.39 ± 4.01, p ¼ 0.027), tumor size
(3.35 ± 1.36 vs. 2.66 ± 1.52 cm, p < 0.011), and CEA level
(10.31 ± 23.34 vs. 4.45 ± 9.47 ng/mL, p ¼ 0.013). Among
those with clinical Stage I tumors, 16 patients (16/37, 43.24%)
Table 1
Characteristics of patients with or without tumor recurrence after resection for







Male 101 (45.09) 16 (43.24) 0.834
Female 123 (54.91) 21 (56.76)
Histopathology
Adenocarcinoma 193 (86.16) 33 (89.19) 0.616
Other 31 (13.84) 4 (10.81)
Differentiation
Well 94 (41.96) 8 (21.62) 0.002
Moderate 89 (39.73) 13 (35.14)
Poor 41 (18.3) 16 (43.24)
Location
Central 113 (50.45) 23 (62.16) 0.186
Peripheral 111 (49.55) 14 (37.84)
Survival
Yes 209 (93.3) 17 (45.95) <0.001
No 15 (6.7) 20 (54.05)
LVSI
Absent 207 (92.41) 29 (78.38) 0.007
Present 17 (7.59) 8 (21.62)
p-stage
I 159 (70.98) 20 (54.05) 0.022
II 37 (16.52) 10 (27.03)
III 28 (12.5) 6 (16.22)
IV 0 (0) 1 (2.7)
Age (y) 61.21 ± 12.50 62.62 ± 10.1 0.513
SUVmax 4.39 ± 4.01 6.06 ± 3.98 0.027
Tumor size (cm) 2.66 ± 1.52 3.35 ± 1.36 < 0.011
CEA (ng/mL) 4.45 ± 9.47 10.31 ± 23.34 0.013
Data are presented as n (%) or mean ± SD.
CEA ¼ carcinoembryonic carcinogen; LVSI ¼ lymphovascular space inva-
sion; p-stage ¼ pathology stage; SCC ¼ squamous cell carcinoma;
SUVmax ¼ maximum standard uptake value.
a Significance was assessed using c2 tests. Statistically significant p values
are depicted in bold.
Fig. 1. The relationship of overall survival rate with and without recurrence in
pathological Stage I nonsmall cell lung cancer.
Table 2
Multiple logistic regression analysis for the risk factors of postoperative
recurrence in the patients with pathological Stage I nonsmall cell lung cancer.
Factors OR (95% CI) pa
SUVmax  3.3 0.497 (0.495e1.485) 0.481
CEA  3.5 ng/mL 1.995 (0.149e0.450) 0.158
Tumor size > 2 cm 2.141 (0.130e0.418) 0.143
Tumor differentiation 3.581 (0.124e0.359) 0.058
LVSI 5.374 (1.285e5.061) 0.020
CEA ¼ carcinoembryonic carcinogen; CI ¼ confidence interval;
LVSI ¼ lymphovascular space invasion; OR ¼ odds ratio;
SUVmax ¼ maximum standard uptake value.
a Statistically significant p values are depicted in bold.
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had poor tumor differentiation. The aggressiveness of tumors
was associated with postoperative recurrence (p < 0.001). In
the group without recurrence, eight patients (7.6%) had been
identified with LVSI versus 17 patients (46%) in the recur-
rence group. Sixty-five patients (65/224, 29.02%) in the group
without recurrence had postoperative upstaging versus 17
patients (17/37, 45.95%) with recurrence.
According to the pathological stage, we selected 179 pa-
tients with pathological Stage I NSCLC to investigate pre-
dictors of postoperative recurrences. Fig. 1 reveals the
relationship between postoperative recurrence and overall
survival in patients with pathological Stage I NSCLC. The
median survival rate was 94.87 months for patients without
recurrence versus 71.46 months for patients with recurrence
(p < 0.001). Therefore, surgical outcome of these patients
is associated with postoperative recurrences. In the multiple
logistic regression analysis for the risk factors of postoperative
recurrence in patients with pathological Stage I NSCLC
(Table 2), tumor differentiation [odds ratio (OR): 3.581,
p ¼ 0.058] and LVSI (OR: 5.374, p ¼ 0.020) were indepen-
dent factors associated with postoperative recurrence. Figs. 2and 3 show the overall survival curves with LVSI and tumor
differentiation. Preoperative SUVmax  3.3 (OR: 0.497,
p ¼ 0.481), CEA  3.5 ng/mL (OR: 1.995, p ¼ 0.158), and
tumor size > 2 cm (OR: 2.141, p ¼ 0.143) did not predict
postoperative recurrences. The overall recurrent rate in pa-
tients with clinical Stage I NSCLC was 14.17% (11.17% for
pathology Stage I and 20.73% for other stages).
4. Discussion
Lung cancer has the highest incidence and mortality rates
of any major cancer worldwide. The 5-year survival rate has
Fig. 2. The relationship of overall survival rate with and without lymphovas-
cular space invasion in patients with pathological Stage I nonsmall cell lung
cancer.
Fig. 3. The relationship of overall survival rate with and without poorly
differentiated tumor in patients with pathological Stage I nonsmall cell lung
cancer.
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and 58% for patients with pathological Stage IB.6 In our study,
we used the same population to probe surgical outcome on the
occurrence of postoperative recurrence. Fig. 1 shows signifi-
cant differences between overall survival and postoperative
recurrences in patients with pathological Stage I NSCLC. The
survival rate is strongly associated with postoperative recur-
rence, which mechanism was not well established to date.
Godfrey et al3 stated that one possible reason for this may be
that those patients with a poor outcome actually have more
extensive disease, with occult locoregional and/or distant
metastasis than originally identified by routine pathologic
staging techniques. One of the most convincing etiology of
postoperative recurrence was occult tumor cell spread to
lymph nodes or bone marrow in patients with NSCLC.3 Bis-
was et al7 thought the detection of bone marrow micrometa-
stasis changes the staging and management of lung cancer,
especially in NSCLC, where treatment with curative intent is
planned, which can be suitably done by morphological study
of bone marrow aspirate and biopsy. However, the cost effect
of bone marrow aspiration is high and the invasiveness of the
procedure may produce more complications. Therefore, we
searched clinicopathologic factors, which were cost-effective
and available after surgery, to predict postoperative re-
currences in patients with pathological Stage I NSCLC. Then,
we could optimize the patient selection for postoperativelyadjuvant treatment to reduce recurrent rate and improve sur-
vival rate. In our data of postoperative recurrence, the poor
prognostic factors were poor tumor differentiation, LVSI,
advanced pathology stage, SUVmax of tumor, tumor size, and
CEA level in patients with clinical Stage I NSCLC (Table 1).
Furthermore, only tumor differentiation and LVSI were iden-
tified as independent predictors in patients with pathological
Stage I NSCLC for postoperative recurrence.
Preoperative clinical staging is a key factor influencing the
decision regarding initial therapy for patients with lung cancer.
In this regard, PETeCT with fluorodeoxyglucose (18F) uptake
(FDG) plays an established role in the treatment of patients
with NSCLC. FDG uptake, which reflects the tumor's glucose
metabolic rate, varies widely and depends on the histopathol-
ogy type and aggressiveness of the tumor.8,9 Consideration of
this parameter enhances the accuracy of clinical staging,
improving patient selection for surgical treatment. Several
studies have reported that the preoperative SUVmax has
prognostic value in patients with early stages of NSCLC.10,11
Koo et al12 investigated factors associated with recurrence in
310 patients with Stages I or II disease. There were 106 re-
currences in the study population and SUVmax  4.5 was
found to be an independent predictor of recurrence after
resection, with an OR of 5.45. In addition, Shiono et al13
demonstrated that SUVmax  4.7 was found to be an inde-
pendent predictor of recurrence in patients with Stage I
NSCLC. These two studies did not stratify patients based on
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more predictive for locoregional than for distant recurrences. In
another study, subgroup analysis found that SUVmax > 5 was
associated with distant recurrences, whereas the predictive
nature of SUVmax > 5 did not reach statistical significance
among patients with locoregional recurrences.14 It is important
for the clinician to understand that SUVmax is a semi-
quantitative index and can vary from one center to another.
Although the metabolic activity of tumors has been shown to
contribute significant information in terms of prognosis,15,16
the cutoff values for SUV measurements vary widely, making
their clinical application difficult. In our study, the cutoff point
of SUVmax of 3.3 was used according to our previous study.17
However, the SUVmax of our results did not show statistical
significance in prediction of postoperative recurrences.
There was concordance between the pathological stage and
the preoperative clinical stage in 68.6% of patients in the
current study. Eighty-two patients (31.4%) had advanced dis-
ease after surgery. This rate was higher than the rates of
upstaging tumors of 14.3e17% reported in the literature.18,19
Kelsey et al20 reported that the overall risk of recurrence
was 36% after surgical resection for patients with Stages I or II
NSCLC. Varlotto et al21 investigated factors associated with
recurrence in 373 patients with Stages IeIIIA NSCLC who
underwent resection. An advanced pathology stage was asso-
ciated with an increased risk of distant recurrence. Although
these two studies established the importance of the patholog-
ical stage for the risk of recurrence, they used the 6th edition
and not the most recent 7th edition of the TNM staging system.
Pepek et al22 compared the ability of the 7th edition TNM
staging systems to detect locoregional recurrence in compar-
ison to the 6th edition. Converting from the system used in the
6th edition to that in the 7th edition resulted in a 21% migration
in stage classification (13% up-staged and 8% downstaged).
This might explain the high rate of postoperative upstaging in
our study, because we used the 7th edition of the TNM staging
system for all patients. In our study, the recurrent rate was
14.17% (11.17% for pathological Stage I and 20.73% for non-
Stage I patients). The 47 patients with pathologic Stage II and
34 patients with pathologic Stage III were upstaged because of
positive nodal status proved by pathologists. The only patient
with pathologic Stage IV had so minimal pleural effusion that
it was hard to detect in imaging studies. The malignant pleural
effusion was found during operation and confirmed after
complete surgery.
Sublobar resection has been found to be an independent
predictor of locoregional recurrence.14 The tumor size in that
report was not associated with an increased risk of recurrence
in the sublobar resection group (2.3 cm in the group with
recurrence, 2.2 cm in the group without recurrence; p < 0.3).
By contrast, Bando et al23 reported that a higher recurrence
rate is associated with sublobar resection in patients with tu-
mors larger than 2 cm. In their study, patients with tumors
smaller than 2 cm had locoregional recurrence rates of 1.9%
compared with 33% in patients with tumors larger than 2 cm.
The different conclusions in these studies might be associated
with the larger sample size in the former study and the fact thatonly 50% of the patients underwent wedge resection. By
contrast, in the latter study, all patients underwent segmen-
tectomy. In our study, only 16 patients had wedge resection
and others underwent lobectomy. For patients with tumor
diameter smaller than 2 cm, the postoperative recurrence rate
was 6.1% versus 19.4% for patients with tumors larger than
2 cm. After adjustment for the other factors, tumor size with a
cutoff of 2 cm was not found to be an independent predictor in
the multiple logistic regression analysis in patients with
pathological Stage I NSCLC.
Histopathology markers were found to be prognostic pre-
dictors in patients with NSCLC.24 CEA is a well-known tumor
marker for substantial malignant tumors, including NSCLC.
Evaluating serum CEA level is useful for monitoring response
to chemotherapy and predicting relapse of advanced
NSCLC.25 Sawabata et al26 assessed 297 consecutive patients
with clinical Stage I NSCLC for evaluation of CEA level and
the upper limit of normal defined as 7.0 ng/mL. They saw
CEA level as a useful predictor of survival for patients with
clinical Stage I NSCLC, and a persistently high CEA level
after surgery as an especially strong indicator of a very poor
prognosis. In another study, Buccheri and Ferrigno27 reported
that the frequency of abnormal serum concentrations of CEA
is low (17%), but it is important to identify such a small group
of high-risk patients as many of them (55% and 70% of those
with a CEA value in excess of, respectively, 5 ng/mL and
10 ng/mL, normal reference values < 5 ng/mL) will develop
an early postoperative recurrence. Although there was a sig-
nificant difference in the serum CEA level between the two
groups in our study, higher serum CEA level ( 3.5 ng/mL)
was not an independent predictor for postoperative recurrence
in multiple logistic regression analysis.
LVSI is an established negative prognostic factor and an
indication for postoperative radiation therapy in several
epithelial malignancies, including cervix, endometrial,
vulvar, and head and neck cancers. Kristin et al28 proposed a
study to evaluate LVSI in patients with early-stage NSCLC
undergoing surgical resection. They found LVSI was asso-
ciated with an increased risk of harboring regional lymph
node involvement and also an adverse prognostic factor for
the development of distant metastases and long-term sur-
vival. National comprehensive cancer network clinical
practice guidelines in NSCLC (version 1.2014, page NSCL-
3) showed that high-risk factors may include poorly differ-
entiated tumors (including lung neuroendocrine tumors),
vascular invasion, wedge resection, tumor larger than 4 cm,
visceral pleural involvement, and incomplete lymph node
sampling. These factors independently may not be an indi-
cation and may be considered when determining treatment
with adjuvant chemotherapy. Therefore, adjuvant chemo-
therapy is still equivocal for high-risk patients with patho-
logical Stage I NSCLC. In our study, tumor differentiation
and LVSI were independent predictors of postoperative
relapse for pathological Stage I NSCLC. Risk factors of
postoperative recurrence in patients with pathological Stage I
NSCLC may enable us to optimize the patient selection for
postoperative adjuvant therapies to reduce recurrent rate, and
421Y.-Y. Chen et al. / Journal of the Chinese Medical Association 77 (2014) 416e421further studies are needed to investigate the outcomes of
adjuvant treatment in high-risk patients.
As a retrospective, single-institute study, patient selection
bias and time-trend bias were inevitable. In addition, we did not
address the risk factors for different recurrence patterns
(locoregional and distant). It was difficult to obtain perfor-
mance status from the charts. Although performance status is
clearly an important factor in Stage IV NSCLC, its importance
in Stage I disease has not yet been established. Lack of data
about performance status might have little significance in the
analysis of death and recurrence in our study. The 261 patients
were operated on by different surgeons; it is generally recog-
nized that different surgeons have different levels of dexterity,
leading to different rates of recurrence. Furthermore, the fact
that the predictors demonstrated in our study were not all
consistent with other reports highlights the possibility of false
positive findings. Further studies of clinical information com-
bined with histopathological markers might provide valuable
indicators for recurrences. Prospective multi-institutional
studies are mandatory to further validate the predictors of
recurrence in pathological Stage I NSCLC.
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